A Nationwide Study on the Seroprevalence of Measles, Mumps, and Rubella in Iranian Children and Adolescents.
Adolescents
Children
Iran
Measles
Mumps
Rubella
Journal
Iranian journal of public health
ISSN: 2251-6093
Titre abrégé: Iran J Public Health
Pays: Iran
ID NLM: 7505531
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
10
07
2020
accepted:
21
09
2020
entrez:
22
7
2022
pubmed:
23
7
2022
medline:
23
7
2022
Statut:
ppublish
Résumé
Assessing the prevalence of infections, which are preventable by vaccination, is crucial to monitor the vaccination program efficacy, and it can demonstrate the gaps in population immunity. The current study attempted to assess the specific Immunoglobulin (IgG) antibody against measles, mumps, and rubella (MMR) in Iranian children and adolescents, years after their vaccination. This cross-sectional study was conducted in Iran. Serum samples of 2100 students, aged 7-18 years, included in a national health survey, were tested for MMR antibodies by ELISA assay. Multistage random cluster sampling was used to select subjects from 30 provinces in Iran. Overall, 1871, 1718, and 1678 serums were tested for measles, mumps, and rubella antibodies, respectively. The prevalence of positive test was 1231 (65.8%) for measles, 1327 (77.2%) for mumps and 1344 (80.1%) for rubella. Despite high vaccination coverage in Iran, IgG antibody against measles, mumps, and rubella was not detected in a considerable proportion of children and adolescents aged 7-18 years. In case of contacts with residents of other countries, where measles or rubella have not yet been eliminated, it may create problems for Iranian children.
Sections du résumé
Background
UNASSIGNED
Assessing the prevalence of infections, which are preventable by vaccination, is crucial to monitor the vaccination program efficacy, and it can demonstrate the gaps in population immunity. The current study attempted to assess the specific Immunoglobulin (IgG) antibody against measles, mumps, and rubella (MMR) in Iranian children and adolescents, years after their vaccination.
Methods
UNASSIGNED
This cross-sectional study was conducted in Iran. Serum samples of 2100 students, aged 7-18 years, included in a national health survey, were tested for MMR antibodies by ELISA assay. Multistage random cluster sampling was used to select subjects from 30 provinces in Iran.
Results
UNASSIGNED
Overall, 1871, 1718, and 1678 serums were tested for measles, mumps, and rubella antibodies, respectively. The prevalence of positive test was 1231 (65.8%) for measles, 1327 (77.2%) for mumps and 1344 (80.1%) for rubella.
Conclusion
UNASSIGNED
Despite high vaccination coverage in Iran, IgG antibody against measles, mumps, and rubella was not detected in a considerable proportion of children and adolescents aged 7-18 years. In case of contacts with residents of other countries, where measles or rubella have not yet been eliminated, it may create problems for Iranian children.
Identifiants
pubmed: 35866127
doi: 10.18502/ijph.v51i2.8694
pii: IJPH-51-409
pmc: PMC9273495
doi:
Types de publication
Journal Article
Langues
eng
Pagination
409-415Informations de copyright
Copyright © 2022 Nokhodian et al. Published by Tehran University of Medical Sciences.
Déclaration de conflit d'intérêts
Conflict of interest None of the authors has any financial that could influence or bias the content of the paper.
Références
Arch Iran Med. 2013 Jan;16(1):38-41
pubmed: 23273235
PLoS One. 2014 Feb 20;9(2):e89361
pubmed: 24586717
Pediatr Infect Dis J. 2007 Dec;26(12):1137-41
pubmed: 18043452
Nutrition. 2021 Oct;90:111307
pubmed: 34116487
Int J Epidemiol. 1982 Mar;11(1):5-14
pubmed: 7085179
East Mediterr Health J. 2009 Mar-Apr;15(2):295-301
pubmed: 19554975
J Trop Pediatr. 2011 Oct;57(5):347-51
pubmed: 21078605
PLoS One. 2012;7(8):e42867
pubmed: 22880124
Clin Obstet Gynecol. 2012 Jun;55(2):550-9
pubmed: 22510638
Emerg Infect Dis. 2013 Mar;19(3):357-64
pubmed: 23618523
East Mediterr Health J. 2004 Jul-Sep;10(4-5):468-73
pubmed: 16335636
J Infect Dis. 2011 Jul;204 Suppl 1:S305-11
pubmed: 21666178
MMWR Morb Mortal Wkly Rep. 2009 Nov 20;58(45):1270-4
pubmed: 19940833
Saudi Med J. 2005 Oct;26(10):1551-4
pubmed: 16228054
Lancet. 1984 Jan 14;1(8368):91-4
pubmed: 6140434
East Mediterr Health J. 2015 Sep 08;21(6):396-402
pubmed: 26369998
Hum Vaccin Immunother. 2016 Dec;12(12):3118-3124
pubmed: 27458680
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD004407
pubmed: 22336803
Int J Prev Med. 2017 Jan 23;8:4
pubmed: 28217266
J Res Health Sci. 2017 Aug 05;17(3):e00387
pubmed: 28878113
PLoS One. 2013 Jun 25;8(6):e66771
pubmed: 23825562